Taysha Gene Therapies (TSHA) Other Non-Current Liabilities (2020 - 2026)

Taysha Gene Therapies has disclosed Other Non-Current Liabilities across 7 years of filings, most recently posting $1.6 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $1.6 million, up 31.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (up 31.83% YoY), and the FY2025 annual result was $1.6 million, up 18.56% from the prior year.
• Other Non-Current Liabilities came in at $1.6 million for Q1 2026 at Taysha Gene Therapies, up from $1.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $42.1 million in Q1 2024 to a low of $1.2 million in Q1 2025.
• The 5-year median for Other Non-Current Liabilities is $3.5 million (2022), against an average of $7.0 million.
• Across the five-year window, Other Non-Current Liabilities jumped 952.17% in 2024 and slumped 97.15% in 2025, its largest moves.
• Taysha Gene Therapies' Other Non-Current Liabilities stood at $4.1 million in 2022, then sank by 61.82% to $1.6 million in 2023, then fell by 16.99% to $1.3 million in 2024, then gained by 18.56% to $1.6 million in 2025, then rose by 1.93% to $1.6 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.6 million (Q1 2026), $1.6 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.